In 105 boys and young men enrolled in the HOPE-3 trial, patients given deramiocel every three months for a year had 54% ...

Capricor shows positive HOPE-3 results with endpoints met, regulatory uncertainty, and a strong cash runway into 2026. Find ...

Capricor Therapeutics shares gained after analysts said they believe the company can achieve profitability by 2028. The stock rose 8.4% to $29.14 and hit its 52-week high of $14.87 earlier in the ...

Capricor Therapeutics faces high regulatory risks for its DMD therapy. Get expert analysis on trial data and FDA challenges.

Just last week, Shkreli had identified Capricor as his next major biotech short target, co-authoring a lengthy report and ...

Six months after receiving a surprise rejection due to what the FDA called “lack of substantial evidence of effectiveness,” ...

Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key ...

Capricor Therapeutics has seen its modeled fair value estimate jump from about $20.60 to roughly $44.56 per share, as analysts grow more confident in Deramiocel's path from the clinic to ...

Capricor jumps after Phase 3 data show Deramiocel improves heart function and slows muscle decline in Duchenne muscular ...

Piper Sandler raised the firm’s price target on Capricor Therapeutics (CAPR) to $45 from $20 and keeps an Overweight rating on the shares. The ...

Shares quadrupled now that the company appears on track to reverse an earlier FDA rejection of what could be the first ...

Capricor Therapeutics said Wednesday that its cell therapy significantly improved muscle and heart function in patients with ...